STAT3 is a latent transcription factor that plays a vital role in the transmission of extracellular signal from receptors to the nucleus. It has been regarded as a master transcription factor due to its role in the regulation of a broad spectrum of genes, which can contribute to oncogenesis. Persistent activation of STAT3 and deregulation of its signaling has been observed in various human cancers including head and neck squamous cell carcinoma (HNSCC). In the present work, we identified brusatol (BT) as a potential blocker of STAT3 signaling pathway in diverse HNSCC cells. The data from the cell-based experiments suggested that BT-induced cytotoxicity and abrogated the activation of STAT3 and that of upstream kinases such as JAK1, JAK2, and Src. It reduced the levels of nuclear STAT3 and its DNA binding ability. BT treatment increased annexin-V-positive cells, promoted procaspase-3 and PARP cleavage, and downregulated the mRNA and protein expression of diverse proteins (Bcl-2, Bcl-xl, survivin) in HNSCC cells. Taken together, brusatol can function as a promising inhibitor targeting STAT3 signaling pathway in HNSCC.
Introduction
Head and neck cancer is a diverse set of cancers that stems predominantly from the squamous cell lining of mouth, throat, and nose and referred as head and neck squamous cell carcinoma (HNSCC) [1] . It accounts for approximately 4% of cancers and over 500,000 new cases are reported annually worldwide [2, 3] . Smoking, tobacco chewing, alcohol intake, and human papillomavirus infections are identified as potential risk factors of HNSCC [4] . Surgical procedures such as transoral robotic surgery, laser surgery, and non-surgical options such as radiation therapy along with chemotherapy are the choice of treatment for managing HNSCC [5] .
The chemical structure of BT is presented as Figure 1A . We initially explored the effect of BT on the viability in a panel of HNSCC cells such as UMSCC 47, UD SCC2, JMAR, Tu167, LN686, YD-10B, HN-9, and FaDu using MTT assay. These cells were treated with different doses (1, 5, or 10 nM) of BT for 24 h and cell viability was measured. We observed the reduction in cell viability on treatment with BT in a dose-dependent manner in all the tested cells ( Figure 1B ). We also deciphered the effect of BT on normal HaCaT cells and did not observe any substantial cytotoxicity at any tested dosage. The IC 50 values for each cell line can be found in the box on the right ( Figure 1B ).
BT Inhibited Constitutive STAT3 Phosphorylation in UD SCC2, JMAR, YD-10B Cells
Constitutive phosphorylation of STAT3 at Tyr705 has been encountered in several types of cancer cells and is responsible for the dimerization of phosphorylated STAT3 and its subsequent nuclear translocation. Further, we examined the result of BT exposure on the constitutive phospho-STAT3 levels in UMSCC 47, UD SCC2, JMAR, Tu167, LN686, YD-10B, HN-9, FaDu, and HaCaT cells. Figure 1C demonstrated that all the tested HNSCC cell lines show constitutive STAT3 phosphorylation. Interestingly, BT inhibited STAT3 (Tyr705) activation only in UD SCC2, JMAR, YD-10B cells, and the levels of total STAT3 protein content were not affected ( Figure 1C ). These results suggest that, BT may interfere with the STAT3 dimerization and subsequent events by downregulation of constitutive phosphorylation.
BT Failed to Suppress STAT3 Activation in A549 and DU145 Cells
We next investigated whether BT could modulate constitutive STAT3 activation in human prostate and lung cancer cell lines. Because A549 and DU145 cells can express constitutive STAT3 activation, we investigated whether BT could also target STAT3 phosphorylation in these cells. Interestingly it was noted that BT did not inhibit STAT3 activation in A549 and DU145 cells ( Figure 1D ).
BT Mitigated STAT3 Activation More Effectively than Stattic in UD SCC2 Cells
We next compared the STAT3 inhibitory efficacy of BT with stattic, a selective small molecule STAT3 inhibitor at the same concentration. The results demonstrated that stattic inhibited STAT3 at 5 nM in UD SCC2 cells, but the effect was less pronounced when compared to BT ( Figure 1E ), thereby suggesting that BT may act as a more potent inhibitor of STAT3 signaling than stattic.
BT Abrogated DNA Binding Ability of STAT3
Phosphorylation of Tyr705 is a critical event in STAT3 dimerization, nuclear localization and binding to specific response elements to induce gene transcription [42, 43] . Therefore, we next determined the consequence of BT treatment on the DNA binding ability of STAT3. The EMSA results showed a significant reduction in STAT3-DNA-binding activities on treatment with BT in the nuclear extracts of UD SCC2, JMAR, YD-10B cells but not in FaDu cells (Figure 2A ). These results infer that BT selectively reduces the DNA binding ability of STAT3. Oct-1 was used as a loading control. 

BT Repressed the Constitutive Phosphorylation of Upstream Kinases
JAKs and Src are the upstream kinases that are responsible for the activation of STAT3 protein in the cytoplasm [44, 45] . We probed the action of BT on the constitutive activation of JAK1, JAK2, and Src in UD SCC2, JMAR, YD-10B, and LN686 cells. We observed the significant reduction in phosphorylation of JAK1 (Tyr1022/1023), JAK2 (Tyr1007/1008), and Src (Tyr416) on treatment with BT in UD SCC2, JMAR, YD-10B cells but not in LN686 cells ( Figure 2B ). The total protein levels of JAK1/2 and Src were not affected. These results indicated that BT induces abrogation of STAT3 signaling by interfering with the activities of all the tested non-receptor tyrosine kinases in UD SCC2, JMAR, YD-10B cells.
BT Reduced the Nuclear STAT3 Level in HNSCC Cells
The phosphorylated STAT3 monomers can undergo dimerization and move into nucleus to drive the expression of target genes. We next examined the distribution of STAT3 in BT treated and untreated cells using immunocytochemistry ( Figure 2C ). We observed the reduction in the nuclear localization of STAT3 in UD SCC2, JMAR, YD-10B cells on BT treatment. Since there was a significant reduction in the phosphorylation of STAT3, a decline in the nuclear pool of STAT3 can also be expected. These findings are consistent with the results of the previous experiments, thus establishing the inhibitory effect of BT on STAT3 signaling cascade.
BT Downregulated the Protein Expression of STAT3-Driven Genes
Genes that code for the proteins which are entangled with the regulation of apoptosis, cell cycle, proliferation, inflammation including Bcl-2, Bcl-xl, COX-2, VEGF, and cyclin D1 are under transcriptional control of STAT3 [46] . Therefore, we next evaluated the effect of BT on the expression of aforementioned gene products. We found that BT substantially downregulated the protein expression of Survivin, Bcl-2, Bcl-xl, COX-2, VEGF, cyclin E, and cyclin D1 in UD SCC2, JMAR, YD-10B, FaDu and LN686 cells ( Figure 3A,B ). However, there was a marginal effect on the expression of gene products in HaCaT cells ( Figure 3C ).
BT Abrogated the Growth of HNSCC Cells
To determine antiproliferative actions of BT on UD SCC2, JMAR, YD-10B, FaDu, and LN686 cells, we treated cells with BT (5 nM) and analyzed their viability in the intervals of every 15 min using RTCA DP Instrument as described in methods. We observed a significant mitigation in the proliferation of tested cells upon BT treatment in a time-dependent manner ( Figure 4A ).
BT Promoted Apoptotic Cell Death
The phosphatidylserine translocation to the outer leaflet of the biological membrane is the critical event observed in the cells undergoing apoptosis which can be detected using annexin V staining [47, 48] . We treated UD SCC2, JMAR, YD-10B cells with 5 nM of BT for 24 h and analyzed for presence of annexin-V-positive cells and observed an augmentation of annexin-V-positive cells from 3.5% to 13.3%, 3.1% to 14.2%, and 2.4% to 12.4% compared with non-treated (NT), respectively ( Figure 4B ).
BT Regulated Caspase-Mediated Apoptosis in HNSCC Cells
Procaspase-3 is the zymogen form which undergoes proteolytic cleavage in response to proapoptotic signals to attain its active form [49] [50] [51] . Further, it acts on various cellular proteins including caspase-activated DNase, lamins, focal adhesion kinase and responsible for cleavage of poly (ADP-ribose) polymerase (PARP) [52, 53] . We evaluated the role of BT in the activation of caspase and cleavage of PARP in treated UD SCC2, JMAR, YD-10B cells. The formation of cleaved caspase-3 is an indicator of activation of procaspase in order to get the proteolytic activity, subsequently leading to the cleavage of PARP. The results demonstrated an increase in cleavage of caspase-3 and PARP on treatment with BT (5 nM) ( Figure 4C ).
Genes that code for the proteins which are entangled with the regulation of apoptosis, cell cycle, proliferation, inflammation including Bcl-2, Bcl-xl, COX-2, VEGF, and cyclin D1 are under transcriptional control of STAT3 [46] . Therefore, we next evaluated the effect of BT on the expression of aforementioned gene products. We found that BT substantially downregulated the protein expression of Survivin, Bcl-2, Bcl-xl, COX-2, VEGF, cyclin E, and cyclin D1 in UD SCC2, JMAR, YD-10B, FaDu and LN686 cells ( Figure 3A,B ). However, there was a marginal effect on the expression of gene products in HaCaT cells ( Figure 3C ). 
BT Abrogated the Growth of HNSCC Cells
To determine antiproliferative actions of BT on UD SCC2, JMAR, YD-10B, FaDu, and LN686 cells, we treated cells with BT (5 nM) and analyzed their viability in the intervals of every 15 min using RTCA DP Instrument as described in methods. We observed a significant mitigation in the proliferation of tested cells upon BT treatment in a time-dependent manner ( Figure 4A ). 
BT Promoted Apoptotic Cell Death
Specific Blockade of Caspase-3 Cleavage Abrogated BT-Induced Apoptosis
We next examined whether BT-induced apoptosis could be modulated by inhibition of caspase-3 using Z-DEVD-FMK (irreversible caspase-3 inhibitor). We found that the BT-induced apoptosis was suppressed by the Z-DEVD-FMK treatment, thus indicating the significance of caspase-3 activation in regulating apoptosis upon BT treatment ( Figure 4D ).
BT Induced STAT3 Inhibition May be Independent of Reactive Oxygen Species (ROS)
Several natural products such as nimbolide may abrogate STAT3 activation by increasing the production of ROS [20] . We further explored the potential role of ROS in BT mediated STAT3 inhibition in YD-10B cells. The results showed that BT treatment did not significantly alter the level of ROS in the cells as evident by flow cytometric analysis ( Figure 4E ). 
In Silico Interaction Studies between BT and SH2 Domain of STAT3
Given the relevance with the structural similarity of previously reported JAK-STAT3 signaling inhibitors, we analyzed the probable binding mode of BT with the SH2 domain of STAT3 protein ( Figure 5A ). The Dock Score (DS) value for the binding of BT towards the SH2 domain of STAT3 was found to be 28.47 kcal/mole, which signifies better affinity of the molecule towards the target. We compared the binding pattern of BT with stattic, a selective inhibitor of STAT3, whose DS was found to be 19 kcal/mole, and it exhibited similar interactions with the key amino acids of SH2 domain of STAT3. The docking results presented that the hydroxyl group of BT is involved in the formation of a hydrogen bond with Asn647 of SH2 domain. The diester sidechain of BT was visualized to be sandwiched between Tyr640 and Phe710 ( Figure 5B ). In summary, the presence of several hydroxyl groups in BT and structural flexibility favor its interaction towards the SH2 domain of STAT3. 
Discussion
STAT3 has been recognized as an attractive therapeutic target in oncology for the development of inhibitors and several agents have been identified to interfere with STAT3 signaling in various cancer models [54] [55] [56] [57] [58] [59] [60] . In an unstimulated cell, STAT3 remains in the cytoplasm in the 
STAT3 has been recognized as an attractive therapeutic target in oncology for the development of inhibitors and several agents have been identified to interfere with STAT3 signaling in various cancer models [54] [55] [56] [57] [58] [59] [60] . In an unstimulated cell, STAT3 remains in the cytoplasm in the unphosphorylated form and upon activation, STAT3 monomer can be phosphorylated at Tyr705 followed by its dimerization with another phosphorylated monomer to translocate into the nucleus. Persistent activation of STAT3 has been observed in a broad range of malignancies including HNSCC [61] and suppression of STAT3 activity could be a strategy to induce apoptosis and to counteract the proliferation of STAT3 positive cells [62] [63] [64] [65] . Here, we elucidated the role of BT in regulating STAT3 signaling cascade in HNSCC cells.
BT has been reported to exhibit prominent anticancer activity in several preclinical cancer models. BT can induce its anticancer effects via modulating multiple cellular signaling events such as Nrf-2, HIF-1α, c-Myc, JNK/p38 MAPK/NF-κB/Stat3/Bcl-2 signaling pathways [31] . Xiang et al. showed that BT can downregulate the phosphorylation of STAT3 in pancreatic cancer cells but the detailed mechanism of inhibition was not deciphered [31] . The cousin compound of BT called bruceantin has also gained significant attention due to its potent antitumor activity in mouse models. However, bruceantin failed to regress tumor in phase-I/II trials and was not pursued further for clinical development [66] . Based on the reported effect of BT in the modulation of various oncogenic and proinflammatory signaling cascades, its effect on STAT3 signaling was examined in HNSCC cells.
Initially, we investigated the effect of brusatol on seven cancer cell lines (LN686, Tu167, FaDu, UMSCC47, HN-9, UD SCC2, JMAR, YD-10B) and observed a decline in the cell viability in all the tested cell lines. LN686, Tu167, JMAR, and FaDu cells displayed relatively high response rate with IC 50 values less than 20 nM, while the others ranged between 21 to 38 nM with a relatively moderate response to BT treatment. Although, BT reduced the viability of all the tested cell lines, it failed to suppress STAT3 phosphorylation in UMSCC 47, Tu167, LN686, HN-9, and FaDu cells. As discussed in the introduction of this report, BT has been reported to induce anticancer activity via modulating diverse signaling cascades such as Nrf2, STAT3, HIF-1, c-Myc, NF-κB, JNK, and p38 pathways. Therefore, STAT3 independent cytotoxic effect of BT in UMSCC 47, Tu167, LN686, HN-9, and FaDu cells could be due to abrogation of these signaling cascades.
Several strategies can be used to terminate STAT3 signaling which encompasses the inhibition of STAT3 phosphorylation by targeting upstream kinases; blockage of STAT3 dimerization by targeting SH2 domains; interfering with nuclear export of STAT3 by targeting karyopherins; and inhibition of STAT3 mediated transcription by blocking its DNA binding domain [67] . Interestingly, our results suggested that this quassinoid BT inhibited the phosphorylation of JAK1 (Tyr1022/1023), JAK2 (Tyr1007/1008), Src (Tyr416) and STAT3 (Tyr705) indicating BT could inhibit STAT3 via modulating several upstream kinases. The pronounced inhibition of signaling cascade was documented using western blotting and EMSA studies. Immunocytochemistry results demonstrated that the reduction in nuclear STAT3 and its accumulation in the cytoplasm upon treatment with BT. This effect may be due to its interaction with the upstream kinases or direct interaction with the SH2 domain of STAT3. Although natural products such as guggulsterone, honokiol, curcumin, resveratrol, flavopiridol and cucurbitacin have been reported to inhibit STAT3 signaling in human malignancies, the precise underlying mechanism in imparting their STAT3 inhibitory activity has not been fully understood [67] . In silico analysis predicted the favorable interaction between BT and SH2 domain of STAT3, and this needs to be validated indirect binding kinetics in future studies.
Previous studies also suggest that the inhibition of STAT3 signaling can regulate apoptosis in tumor cells [68] . As a consequence of BT induced STAT3 inhibition, we observed a decline in the cell viability and increase in apoptosis at sub-micromolar concentrations. Activation of caspase-3 and cleavage of PARP are the major events observed during programmed cell death [69] . Caspase-3 is a death protease that is present in the inactive form and the relaying of the apoptotic signals from initiator caspases (caspase-8 and -9) can lead to the activation of caspase-3 by proteolytic processing [70] . The activated caspase-3 can than cleave PARP, a DNA repair enzyme into larger (89 kDa) and smaller (24 kDa) fragments [71] . The larger fragment possesses catalytic site with reduced DNA binding ability and smaller fragment has a DNA binding domain [72] . The larger fragment moves to cytoplasm upon cleavage; whereas the smaller fragment irreversibly binds to nicked DNA and prevents repair of DNA which can drive the cell towards apoptosis [72] . We observed both the cleavage of caspase-3 and PARP upon treatment with BT in HNSCC cells.
STAT3 can modulate the expression of numerous genes with diverse biological effects including Bcl-2 family proteins, survivin, COX-2, VEGF, and cyclin D1 [46, 73] . Bcl-2 and Bcl-xl are apoptosis suppressor proteins that can interact with pro-apoptotic proteins in order to modulate the process of programmed cell death and transform cells [74] . COX-2 can regulate cancer cell survival and proliferation, inflammation, metastasis, angiogenesis, and resistance to chemotherapy [75] [76] [77] . Survivin belongs to the inhibitor of apoptosis (IAP) protein family and imparts its activity by blocking caspases. High survivin expression has been observed in cancers and its expression may be associated with poor clinical outcome [78] . VEGF is a major growth factor that controls the angiogenesis by interacting with VEGFR [79] and the VEGFR signaling has been identified as negative prognostic factor which can be associated with pathological angiogenesis in human malignancies [79, 80] . Cyclin D1 and E are the cell cycle regulators that are crucial for G1 to S phase transition with their respective cyclin-dependent kinase binding partners. Overexpression of cyclin D1, and cyclin E has been identified to provide proliferative advantage to the tumor cells [81, 82] . Interestingly, BT downregulated the protein expression of Bcl-2, Bcl-xl, survivin, COX-2, VEGF, cyclin D1, and cyclin E.
Overall, aberrant activity STAT3 have been described as a contributing factor for the formation of a tumor, chemoresistance, and poor prognosis in HNSCC [83] . In addition to Nrf-2 modulatory activity, we have explored another underlying molecular mechanism of BT to impart its antitumor activity in tumor cells that display constitutively active STAT3. In conclusion, these findings comprehensively demonstrate that BT may act as an effective inhibitor of STAT3 signaling and it can be a promising drug to test in other STAT3 overexpressing preclinical cancer models. 
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